First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor–receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC)....
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2012
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/df50be203eb746cd82bc4f08172f2614 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|